MyFinsight
Home
Blog
About
Back
Income Statement
Metagenomi Therapeutics, Inc. (MGX)
Metagenomi Therapeutics, Inc. (MGX)
source: myfinsight.com
Comprehensive loss
-$27,560K
(-36.73%↓ Y/Y)
Net loss
-$27,482K
(-38.05%↓ Y/Y)
Unrealized loss on
available-for-sale marketable...
-$78K
(68.67%↑ Y/Y)
Interest income
$1,256K
(-49.46%↓ Y/Y)
Other income
(expense), net
$35K
(150.00%↑ Y/Y)
Net loss before
provision for income taxes
-$27,482K
(-38.35%↓ Y/Y)
Total other income,
net
$1,291K
(14.96%↑ Y/Y)
Loss from operations
-$28,773K
(-37.10%↓ Y/Y)
Total operating
expenses
$28,516K
(-3.34%↓ Y/Y)
Collaboration revenue
-$257K
(-103.02%↓ Y/Y)
Research and development
$22,512K
(0.02%↑ Y/Y)
General and
administrative
$6,004K
(-14.14%↓ Y/Y)
Back